Jpmorgan Chase & CO Acadia Pharmaceuticals Inc Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 441,124 shares of ACAD stock, worth $8.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
441,124
Previous 628,249 29.79%
Holding current value
$8.1 Million
Previous $10.2 Million 33.51%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Dec 26, 2024
SELL
$15.14 - $19.14 $2.83 Million - $3.58 Million
-187,125 Reduced 29.79%
441,124 $6.79 Million
Q3 2024

Nov 08, 2024
SELL
$15.14 - $19.14 $2.83 Million - $3.58 Million
-187,125 Reduced 29.79%
441,124 $6.79 Million
Q2 2024

Dec 26, 2024
BUY
$14.62 - $18.42 $2.74 Million - $3.45 Million
187,125 Added 42.42%
628,249 $10.2 Million
Q2 2024

Aug 12, 2024
BUY
$14.62 - $18.42 $2.24 Million - $2.82 Million
153,245 Added 32.26%
628,249 $10.2 Million
Q1 2024

Dec 26, 2024
BUY
$17.79 - $30.86 $602,725 - $1.05 Million
33,880 Added 7.68%
475,004 $8.78 Million
Q1 2024

May 10, 2024
SELL
$17.79 - $30.86 $3.31 Million - $5.74 Million
-185,896 Reduced 28.13%
475,004 $8.78 Million
Q4 2023

Dec 26, 2024
BUY
$20.78 - $31.77 $4.57 Million - $6.98 Million
219,776 Added 49.82%
660,900 $20.7 Million
Q4 2023

Feb 12, 2024
BUY
$20.78 - $31.77 $4.22 Million - $6.45 Million
202,985 Added 44.33%
660,900 $20.7 Million
Q3 2023

Nov 14, 2023
BUY
$20.84 - $33.47 $3.69 Million - $5.92 Million
176,923 Added 62.96%
457,915 $9.54 Million
Q2 2023

Aug 11, 2023
SELL
$17.8 - $25.65 $23.2 Million - $33.4 Million
-1,303,792 Reduced 82.27%
280,992 $6.73 Million
Q1 2023

May 18, 2023
BUY
$16.32 - $20.92 $2.6 Million - $3.33 Million
159,068 Added 11.16%
1,584,784 $29.8 Million
Q1 2023

May 11, 2023
SELL
$16.32 - $20.92 $10.9 Million - $14 Million
-669,775 Reduced 31.96%
1,425,716 $26.8 Million
Q4 2022

Feb 13, 2023
BUY
$14.2 - $18.63 $3.36 Million - $4.41 Million
236,530 Added 12.72%
2,095,491 $33.4 Million
Q3 2022

Nov 14, 2022
SELL
$14.11 - $18.27 $673,879 - $872,556
-47,759 Reduced 2.5%
1,858,961 $30.4 Million
Q2 2022

Aug 11, 2022
SELL
$13.01 - $27.22 $5.25 Million - $11 Million
-403,635 Reduced 17.47%
1,906,720 $26.9 Million
Q1 2022

May 11, 2022
BUY
$20.94 - $27.5 $2.27 Million - $2.97 Million
108,179 Added 4.91%
2,310,355 $56 Million
Q4 2021

Feb 10, 2022
SELL
$16.79 - $27.09 $1.9 Million - $3.07 Million
-113,440 Reduced 4.9%
2,202,176 $51.4 Million
Q3 2021

Nov 12, 2021
BUY
$15.78 - $24.77 $36.5 Million - $57.4 Million
2,315,616 New
2,315,616 $38.5 Million

Others Institutions Holding ACAD

# of Institutions
283
Shares Held
158M
Call Options Held
901K
Put Options Held
314K
View Full List

About ACADIA PHARMACEUTICALS INC

ACAD Quotes by TradingView
  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.97B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email